In summary, metabolic regulation via the p53/miR-34 axis may be crucial for tumor suppression and therefore, the development of small-molecule drugs targeting LDHA, SIRT1 and MYC may be a novel strategy for anticancer therapy. This evidence concerns the gene TP53 and neoplasm.